Prediction of antibody persistency from antibody titres to natalizumab

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Prediction of antibody persistency from antibody titres to natalizumab. / Jensen, Poul Erik H; Koch-Henriksen, Nils; Sellebjerg, Finn; Sørensen, Per S.

I: Multiple Sclerosis, Bind 18, Nr. 10, 2012, s. 1493-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Jensen, PEH, Koch-Henriksen, N, Sellebjerg, F & Sørensen, PS 2012, 'Prediction of antibody persistency from antibody titres to natalizumab', Multiple Sclerosis, bind 18, nr. 10, s. 1493-9. https://doi.org/10.1177/1352458512441688

APA

Jensen, P. E. H., Koch-Henriksen, N., Sellebjerg, F., & Sørensen, P. S. (2012). Prediction of antibody persistency from antibody titres to natalizumab. Multiple Sclerosis, 18(10), 1493-9. https://doi.org/10.1177/1352458512441688

Vancouver

Jensen PEH, Koch-Henriksen N, Sellebjerg F, Sørensen PS. Prediction of antibody persistency from antibody titres to natalizumab. Multiple Sclerosis. 2012;18(10):1493-9. https://doi.org/10.1177/1352458512441688

Author

Jensen, Poul Erik H ; Koch-Henriksen, Nils ; Sellebjerg, Finn ; Sørensen, Per S. / Prediction of antibody persistency from antibody titres to natalizumab. I: Multiple Sclerosis. 2012 ; Bind 18, Nr. 10. s. 1493-9.

Bibtex

@article{183600bb62b14854997d2659aabb86ad,
title = "Prediction of antibody persistency from antibody titres to natalizumab",
abstract = "In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.",
author = "Jensen, {Poul Erik H} and Nils Koch-Henriksen and Finn Sellebjerg and S{\o}rensen, {Per S}",
year = "2012",
doi = "10.1177/1352458512441688",
language = "English",
volume = "18",
pages = "1493--9",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "10",

}

RIS

TY - JOUR

T1 - Prediction of antibody persistency from antibody titres to natalizumab

AU - Jensen, Poul Erik H

AU - Koch-Henriksen, Nils

AU - Sellebjerg, Finn

AU - Sørensen, Per S

PY - 2012

Y1 - 2012

N2 - In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.

AB - In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.

U2 - 10.1177/1352458512441688

DO - 10.1177/1352458512441688

M3 - Journal article

C2 - 22454098

VL - 18

SP - 1493

EP - 1499

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 10

ER -

ID: 48569358